Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,184Revenue $M22.0Net Margin (%)-306.0Altman Z-Score52.5
Enterprise Value $M3,799EPS $-0.8Operating Margin %-328.5Piotroski F-Score5
P/E(ttm)--Beneish M-Score7.7Pre-tax Margin (%)-306.0Higher ROA y-yY
Price/Book8.910-y EBITDA Growth Rate %--Quick Ratio22.2Cash flow > EarningsY
Price/Sales1965-y EBITDA Growth Rate %--Current Ratio22.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-18.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M85.9ROIC % (ttm)-108.0Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 48.09249%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 48.09292%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 48.09533%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 48.09570%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 48.09570%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 48.09505%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 48.09505%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 48.09611%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 48.09617%Reduce 23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 48.09538%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 48.09568%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 48.09530%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OBrien Christopher FlintChief Medical Officer 2015-07-20Sell11,250$55-12.56 view
Grigoriadis Dimitri E.Chief Research Officer 2015-07-20Sell19,646$55-12.56 view
Coughlin Timothy PCFO 2015-07-20Sell20,000$55-12.56 view
OBrien Christopher FlintChief Medical Officer 2015-07-13Sell10,000$50-3.82 view
Grigoriadis Dimitri E.Chief Research Officer 2015-07-13Sell10,000$50-3.82 view
Coughlin Timothy PCFO 2015-07-13Sell20,000$50-3.82 view
MITCHELL W THOMASDirector 2015-06-23Sell15,000$49.35-2.55 view
OBrien Christopher FlintChief Medical Officer 2015-06-08Sell10,000$456.87 view
Grigoriadis Dimitri E.Chief Research Officer 2015-06-08Sell10,000$456.87 view
Coughlin Timothy PCFO 2015-06-08Sell60,000$45.086.68 view

Quarterly/Annual Reports about NBIX:

    News about NBIX:

    Articles On GuruFocus.com
    Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
    Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
    Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
    5 Strong Healthcare Stocks For 2012 Mar 24 2012 
    Consider These 5 Healthcare Stocks Now Mar 21 2012 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 

    More From Other Websites
    Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors Sep 03 2015
    Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors Sep 03 2015
    Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference Sep 02 2015
    XBI Pharmaceutical Valuation Rises on Strong Small-Cap Performance Sep 02 2015
    Acadia, Neurocrine, Dyax, and Opko Trade Below 50-Day Moving Average Sep 02 2015
    ICPT and XON Put Pressure on XBI’s Biotechnology Sector Sep 02 2015
    Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference Sep 02 2015
    Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health Aug 25 2015
    3 Top Jefferies Growth Stocks to Buy After Sell-Off Aug 25 2015
    Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study Aug 13 2015
    Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study Aug 13 2015
    NEUROCRINE BIOSCIENCES INC Financials Aug 05 2015
    AbbVie, Inc. Earnings Q2*, 2015 Aug 03 2015
    NBIX: Three More Data Readouts Coming in the Second Half of 2015 - Analyst Blog Jul 30 2015
    NBIX: Three More Data Readouts Coming in the Second Half of 2015… Jul 30 2015
    Edited Transcript of NBIX earnings conference call or presentation 29-Jul-15 9:00pm GMT Jul 29 2015
    Neurocrine reports 2Q loss Jul 29 2015
    Neurocrine reports 2Q loss Jul 29 2015
    Neurocrine Biosciences Reports Second Quarter 2015 Results Jul 29 2015
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK